Eledon Pharmaceuticals, Inc.
NASDAQ:ELDN
4.35 (USD) • At close December 27, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Eledon Pharmaceuticals, Inc. |
Symbool | ELDN |
Munteenheid | USD |
Prijs | 4.35 |
Beurswaarde | 259,865,955 |
Dividendpercentage | 0% |
52-weken bereik | 1.52 - 5.54 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. David-Alexandre C. Gros M.D., Ph.D. |
Website | https://eledon.com |
An error occurred while fetching data.
Over Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)